UNSPSC 51142041: Flupirtine gluconate

This classification denotes an analgesic agent C15H17FN4O2.C6H12O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D7NP6CR89M, chemically known as d-gluconic acid, compd. with ethyl (2-amino-6-(((4-fluorophenyl)methyl)amino)-3-pyridinyl)carbamate, but more generally known as flupirtine gluconate, which bears US NIH Compound Identifier 18608234. European Medicines Agency schedules Flupirtine gluconate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02233MIG.

Most nations, for tariff and trade purposes, schedule flupirtine gluconate under HS 29333999 and SITC 51574. As of Q4 2014, FLUPIRTINE GLUCONATE remains US FDA's Preferred Term for this commodity. SMILES: CCOC(=O)NC1CCC(NC1N)NCC2CCC(CC2)F.C([C@H]([C@H]([C@@H]([C@H](C(=O)O)O)O)O)O)O.

UNSPSC 51142041 Flupirtine gluconate is a Commodity code with minimal alignment between its narrow pharmaceutical scope and the state and local opportunities currently posted under it. Recent solicitations tagged to this code instead reflect demand for broader pharmaceutical procurement — naloxone and drug deactivation systems for emergency response, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products for statewide distribution networks. The actual buying activity involves county health departments, state health and human services commissions, and multistate cooperative purchasing alliances procuring acute-care and chronic-supply medications and medical countermeasures through competitive bidding (IFB), requests for information (RFI), and request-for-proposal (RFP) processes. Vendors responding to these opportunities must comply with E-Verify, drug-free workplace certification, cGMP and Drug Supply Chain Security Act standards, maintain substantial insurance coverage (commercial general liability in the $2 million to $5 million range), and submit detailed product and pricing data through state e-procurement portals or cooperative purchasing systems.

The geographic footprint spans Florida, Texas, and Minnesota through recent activity, with multistate reach through cooperative purchasing vehicles serving Oregon and other participating jurisdictions. Representative recent opportunities include Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026; response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year term with optional one-year renewal; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager and wholesaler channels; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026; due March 26, 2026) for generic pharmaceuticals and OTC products distributed through three authorized wholesalers nationwide, with awards effective July 1, 2026, and evaluation weighted 75 percent on price competitiveness. The code shows little relevant recent activity specific to flupirtine gluconate itself; vendors targeting this taxonomy should assess whether the broader pharmaceutical procurement activity under the code aligns with their product lines and distribution capabilities.